Description
A σ1 receptor ligand and dopaminergic stabilizer; binds to the σ1 receptor and dopamine D2 receptor in the high-affinity state (Kis = 81.3 and 7,521 nM, respectively); increases striatal DOPAC levels and locomotor activity, as well as inhibits amphetamine-induced locomotor activity, in rats at 100 µmol/kg; improves motor function and reduces striatal mHtt aggregates in the R6/2 mouse model of Huntington’s disease at 5 or 6 mg/kg; prevents muscle atrophy and the loss of innervated neuromuscular junctions in the SOD1-G93A mouse model of ALS at 30 mg/kg